Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | ABCC9 | O60706 | 3/20 | 0.36 |
| ▸ | KCNJ11 | Q14654 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.33 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.33 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6218681 | 0.93 | TP53 (0.39) | TP53RAB9AHPGDABCC9KCNJ11 | |
| SCHEMBL29520509 | 0.85 | RAB9A (0.40) | RAB9ATSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL21224168 | 0.85 | RAB9A (0.40) | RAB9ATSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL4858133 | 0.82 | RAB9A (0.36) | RAB9AABCC9KCNJ11MEN1KMT2A | |
| SCHEMBL10018131 | 0.82 | RAB9A (0.43) | TP53RAB9AHPGDMEN1KMT2A | |
| SCHEMBL3711765 | 0.77 | ABCC9 (0.44) | ABCC9KCNJ11MEN1KMT2AABCC8 | |
| SCHEMBL5791363 | 0.77 | ABCC9 (0.35) | RAB9AABCC9KCNJ11MEN1KMT2A | |
| SCHEMBL1587499 | 0.77 | ALOX15 (0.43) | RAB9ATSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL1121729 | 0.77 | KMT2A (0.44) | HPGDMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL5756254 | 0.77 | ALDH1A1 (0.43) | RAB9ATSHRMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1456160-B1 | VITAMIN D ANALOGUES | GALDERMA RES & DEV (FR) | 2010-01-20 | — | — | EP | disclosed |
| US-6924400-B2 | Triaromatic vitamin D analogues | GALDERMA RESEARCH & DEVELOPMENT, SNC (FR) | 2005-08-02 | — | — | US | disclosed |
| EP-1194429-B1 | POTASSIUM CHANNEL OPENERS | ABBOTT LAB (US) | 2005-03-30 | — | — | EP | disclosed |
| EP-1456160-A2 | VITAMIN D ANALOGUES | Galderma Research & Development, S.N.C. (FR) | 2004-09-15 | — | — | EP | disclosed |
| US-20030195259-A1 | Triaromatic vitamin D analogues | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2003-10-16 | — | — | US | disclosed |
| WO-2003050067-A2 | VITAMIN D ANALOGUES | GALDERMA RESEARCH & DEVELOPMENT, SNC (FR) | 2003-06-19 | — | — | WO | disclosed |
| EP-1194429-A1 | POTASSIUM CHANNEL OPENERS | Abbott Laboratories (US) | 2002-04-10 | — | — | EP | disclosed |
| WO-2000078768-A1 | POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2000-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195259-A1 | Triaromatic vitamin D analogues | CYP24A1, CYP2R1, VDR | TP53 657/4885RAB9A 3535/4885HPGD 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.